JAK2 and anemia: Momelotinib is a JAK1/JAK2 inhibitor, which in murine models of anemia in chronic disease, was shown to inhibit bone morphogenic protein receptor kinase activin A receptor type I (ACVR1)–mediated hepcidin expression, which stimulated erythropoiesis [81].